H igh fasting glucose (FG) and insulin (FI) levels are hallmarks of type 2 diabetes mellitus. Since 2007, genomewide association studies (GWASs) of type 2 diabetes mellitus and diabetes mellitus-related quantitative traits have identified 53 common, consistently replicated single-nucleotide variants associated with FG and FI. 1 One especially intriguing and complex region identified as influencing FG is the chromosome 11p11.2 locus. This region contains rs7944584, located in intron 25 of the mitogen-activated protein kinase-activating death domain (MADD) gene, and was associated with a 0.021-mg/dL per (A) allele increase in FG (P=2.0×10 −18 ) in a large GWAS of individuals of European ancestry. 2 In a related GWAS of proinsulin, an additional signal at the 11p11.2 locus was identified for rs10838687 (r 2 with rs7944584=0.074 in HapMap 2 CEU [Utah residents with ancestry from northern and western Europe]), which is intronic in MADD and associated with a 0.08-mg/dL difference in levels of fasting proinsulin (P=1.1×10 −88 ). 3 Thus, the 11p11.2-MADD locus seems to be consistently associated with insulin and glucose regulation, but the region encompasses additional genes plausibly linked to glycemic regulation. Follow-up studies to more precisely localize and characterize genes underlying GWAS-identified signals and to discover functional variants in genes or regulatory regions are a next step to further insights into the genetic Background-Common variation at the 11p11.2 locus, encompassing MADD, ACP2, NR1H3, MYBPC3, and SPI1, has been associated in genome-wide association studies with fasting glucose and insulin (FI). In the Cohorts for Heart and Aging Research in Genomic Epidemiology Targeted Sequencing Study, we sequenced 5 gene regions at 11p11.2 to identify rare, potentially functional variants influencing fasting glucose or FI levels. Methods and Results-Sequencing (mean depth, 38×) across 16.1 kb in 3566 individuals without diabetes mellitus identified 653 variants, 79.9% of which were rare (minor allele frequency <1%) and novel. We analyzed rare variants in 5 gene regions with FI or fasting glucose using the sequence kernel association test. At NR1H3, 53 rare variants were jointly associated with FI (P=2.73×10 −3 ); of these, 7 were predicted to have regulatory function and showed association with FI (P=1.28×10 −3 ). Conditioning on 2 previously associated variants at MADD (rs7944584, rs10838687) did not attenuate this association, suggesting that there are >2 independent signals at 11p11.2. One predicted regulatory variant, chr11:47227430 (hg18; minor allele frequency=0.00068), contributed 20.6% to the overall sequence kernel association test score at NR1H3, lies in intron 2 of NR1H3, and is a predicted binding site for forkhead box A1 (FOXA1), a transcription factor associated with insulin regulation. In human HepG2 hepatoma cells, the rare chr11:47227430 A allele disrupted FOXA1 binding and reduced FOXA1-dependent transcriptional activity. Conclusions-Sequencing at 11p11.2-NR1H3 identified rare variation associated with FI. One variant, chr11:47227430, seems to be functional, with the rare A allele reducing transcription factor FOXA1 binding and FOXA1-dependent transcriptional activity. (Circ Cardiovasc Genet. 2014;7:374-382.)
pathways involved in glycemic regulation and type 2 diabetes mellitus risk. In this study, we conducted high-throughput next-generation deep sequencing at the polygenic 11p11.2 locus to localize previously observed association signals and identify rare, potentially functional variants influencing FG and FI levels.
Methods
The design of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Targeted Sequencing Study, including the study cohort sampling design, laboratory methods for targeted nextgeneration deep sequencing, and rare and common variant statistical analyses, has been described in detail in Lumley et al 4 and Lin et al. 5 These methods are described briefly here, with a focus on details specific to the analysis of FG and FI.
Study Cohort Sample
The CHARGE Targeted Sequencing Study comprised individuals of European ancestry from 3 cohorts that are part of the larger CHARGE Consortium: the Atherosclerosis Risk in Communities (ARIC) study, Cardiovascular Health Study (CHS), and Framingham Heart Study (FHS). 6 The CHARGE Targeted Sequencing Study included a cohort random sample and selected case groups from a variety of related cardiometabolic phenotypes, including a sample of ≈200 participants (100 ARIC study, 50 CHS, 50 FHS) from the high extremes of FI (≥8-hour fast) in individuals without diabetes mellitus, defined as being diagnosed by a physician (ARIC study), treated for diabetes mellitus, or having a fasting glucose (FG) >7 mmol/L (ARIC study, FHS, and CHS). FHS participants with type 1 diabetes mellitus were excluded from selection. Men and women were selected equally from each cohort, giving 3566 individuals with successful sequencing and measured trait available for analysis of FG and FI as continuously distributed quantitative traits. All ARIC study, FHS and CHS subjects provided written informed consent to participate in research protocols that were approved by the University of North Carolina at Chapel Hill, Chapel Hill, NC (ARIC study), Boston University, Boston, MA (FHS), and University of Washington, Seattle, WA (CHS) institutional review boards.
Quantitative Traits Measurement
FG and FI were measured from fasting plasma (FHS) or fasting serum (CHS, ARIC study). [7] [8] [9] In FHS, plasma was collected after a ≥8-hour overnight fast. FG was measured using a hexokinase assay (A-gent glucose test, Abbott, South Pasadena, CA), and FI was measured on frozen specimen using the DPC Coat-A-Count Radio Immuno Assay (total immunoreactive insulin) assay (assay sensitivity, 1.2 µU/mL). In CHS, FG (≥12-hour fast) was measured using a Kodak Ektachem 700 Analyzer assay and FI was measured using a competitive Radio Immuno Assay (Diagnostic Products Corp, Malvern, PA). In ARIC study (after a ≥8-hour fast), FG was measured using the hexokinase/ glucose-6-phosphate dehydrogenase method and FI was measured by radioimmunoassay (125 Insulin kit; Cambridge Medical Diagnosis, Billerica, MA; assay sensitivity, 2 μU/mL).
Targeted Next-Generation Deep Sequencing
Target selection in the CHARGE Targeted Sequencing Study included genomic regions shown to exhibit pleiotropy, or apparent association of a single locus on multiple traits, and included the 11p11.2 locus encompassing ACP2, NR1H3, MADD, MYBPC3, and SPI1. 5 We selected and sequenced regions with high regulatory potential for a total of 16.08 kb, sequenced at a mean depth of 38× across the 5 gene regions ( Table I in the Data Supplement) . Sequence regions at each locus included key variants selected by GWAS trait associations or known gene expression (expression quantitative trait locus [eQTL]) associations, HapMap CEU linkage disquilibrium of r 2 >0.5 with other single-nucleotide polymorphisms identified by GWAS or eQTL approaches, and regions displaying high sequence conservation across mammals and vertebrates (28-species phylogenetic analysis with space/time models conservation scores >500). 10 As detailed in Lin et al, 5 sequencing was performed on the SOLiD next-generation sequencing platform, with cross-validation of sequence-identified genotypes by comparison with genotypes on the Affymetrix Gene Chip 500K Array Set and 50K Human Gene Focused Panel in 1096 FHS samples. A total of 558 single-nucleotide polymorphisms were shared between the 2 platforms. After excluding missing genotypes, 98.0% of genotypes were concordant between the 2 platforms, suggesting high accuracy of the sequenced genotypes.
Variant Classification and Annotation
We classified variants identified by sequencing across the 11p11.2 locus as common if the study-wide minor allele frequency (MAF) in the merged data sets (FHS, CHS, and ARIC study) was ≥1% and rare if the MAF was <1%. Variants were classified as novel if they were not described in dbSNP or the 1000 Genomes Project. 11 Functional prediction annotations were obtained from the RegulomeDB database, 12 which scores variants for regulatory potential and includes data from ENCODE (ENCODE transcription factor ChIP-seq, histone ChIP-seq, FAIRE, and DNase I hypersensitive sites) 12 and other sources (including transcription factor ChIP-seq data available from the NCBI Sequence Read Archive [13] [14] [15] [16] [17] [18] [19] [20] as well as eQTL, [21] [22] [23] [24] [25] [26] [27] [28] [29] dsQTL, 30 and ChIP-exo 31 data) in addition to computational predictions and manual annotations to identify putative regulatory and functional variants. RegulomeDB prediction categories can be found in Table  II in the Data Supplement. Based on RegulomeDB prediction scores, variants were grouped to determine which specific types of variants contributed most to the overall joint variant effect at a locus. For example, variants likely to influence local gene transcription have prediction scores 1 to 3 which includes transcription factor binding sites, transcription factor motifs, DNase footprints, and DNase peaks.
Follow-Up Genotyping of Rare Variants in FHS
To test whether chr11:47227430 had a discernable effect on FI levels, we genotyped the variant in FHS subjects using TaqMan (ABI PRISM 7700 HT Sequence Detection System, Applied Biosystems, Foster City, CA). Genotyping success rate was >98%. Genotyping quality was tested using duplicate samples in each 384-well assay along with synthetic oligonucleotide positive controls for the rare A/G variant. The average agreement rate comparing duplicates was >99%, and the agreement of positive controls with the expected genotype was 100%.
Electrophoretic Mobility Shift Assays
Allele-specific binding efficiency of the forkhead box A1 (FOXA1) transcription factor to the motif around chr11:47227430 site was evaluated using electrophoretic mobility shift assays. FOXA1 protein was expressed using the TnT Coupled Reticulocyte Lysate System (Promega, Madison, WI) programmed with a expression vector containing FOXA1 cDNA cloned into the KpnI and BamH1 sites of pcDNA3.1(+) (Invitrogen, Burlington, Ontario, Canada). Expression of FOXA1 protein in the reticulocyte lysate was confirmed by Western blotting. DNA oligonucleotides were annealed and labeled using the DIG Gel Shift Labelling Kit (Roche Applied Science, Laval, Quebec, Canada). For electrophoretic mobility shift assay, 5 µL of programmed reticulocyte lysate was incubated with 0.6 pmol of digoxigenin-labeled probe in electrophoretic mobility shift assay binding buffer (DIG Gel Shift Labelling Kit, Roche Applied Science, Laval, Quebec, Canada) supplemented with 100 ng single-stranded nonspecific oligonucleotide 32 and 50 ng denatured single-stranded DNA. Unlabeled competitor oligonucleotides were added at 5× to 100× molar excess, and the reaction was incubated for 20 minutes at room temperature. DNA-protein complexes were separated using a nondenaturing polyacrylamide gel (5% acrylamide/ bisacrylamide [29:1] ; 0.5X Tris/Borate/EDTA), detected by chemiluminescence using an alkaline phosphatase-conjugated antibody (Anti-Digoxigenin-AP, Roche) and imaged using autoradiography. Sequences for these oligonucleotides are provided in Table V in the Data Supplement. June 2014
Transient Transfection Assays
Allele-specific effects of chr11:47227430 on FOXA1-mediated gene transcription were studied using dual luciferase assay experiments. Chromatin immunoprecipitation studies completed by the ENCODE project show that chr11:47227430 is located in a 280bp region of active chromatin in HepG2 cells that binds FOXA1. 33 This 280-bp DNA fragment (containing the reference G allele) was amplified and cloned into the pGLuc Mini-TK expression vector (New England Biolabs, Whitby, Ontario, Canada), which contains a gaussia luciferase reporter gene controlled by a minimal promoter from the Herpes Simplex Virus thymidine kinase. Overlap extension polymerase chain reaction was used to create a second reporter containing the FI-associated A allele at the chr11:47227430 site. To isolate the effects of FOXA1 in this region, a second set of reporter plasmids was constructed that contained a 40-bp genomic region centered on chr11:47227430 and flanked by ≈2 helical turns of DNA on each side. As a positive control for FOXA1-mediated transcription, we tested expression of a reporter plasmid containing a single copy of the well-characterized albumin gene enhancer FOXA1 motif or FOXA1 binding (FB, 5′-TGTTTGTTCTT-3′). 34 The control firefly luciferase expression vector (pGL3 Control Vector, Promega, Catalog No. E1741) was used to correct for transfection efficiency. All the constructs were verified by Sanger DNA sequencing. Transfections were performed in quadruplicate using HepG2 cells grown in DMEM (Life Technologies, Burlington, Ontario, Canada) supplemented with 10% fetal bovine serum (Sigma-Aldrich, Oakville, Ontario, Canada). The cells were seeded in 96-well plates, grown to 50% confluence, and cotransfected with 100 ng of plasmid DNA using Trans-LT1 transfection reagent (Mirus Bio, Madison, WI). The transfection mix contained 86 ng pGluc Mini-TK reporter, 4 ng internal control (25:1 ratio), and 10 ng pcDNA3.1(+)-FOXA1 or pcDNA3.1(+) alone. The cells were lysed 48 hours after transfection and measured gaussia and firefly luciferase activities using the Dual Luciferase Reporter Assay System (Promega, Madison, WI) according to the manufacturer's instructions. Cells transfected with an empty pGluc Mini-TK backbone were used to adjust for background activity. The responsiveness of each construct to FOXA1 coexpression was measured by comparing the transcriptional activity of each construct in cells transfected with pcDNA3.1-FOXA1 with cells transfected with empty pcDNA3.1.
Statistical Analyses
All analyses were adjusted for age, sex, and study design variables (ie, clinic site for CHS and ARIC study and recruitment cohort for FHS). FG was analyzed as per mg/dL. FI, in pmol/L, was naturally log transformed to improve normality and was additionally adjusted for body mass index (BMI), measured using standard methods as previously described. 35 The analytic strategy for sequence-based variants, outlined in brief below, followed the approach described in detail in Lumley et al 4 and Lin et al. 5 We used 2-sample t tests and χ 2 tests for analysis of functional assay results and of trait values by genotype category for follow-up genotyping in FHS.
Rare Variant Analyses
Rare variants within each of the 5 11p11.2 gene regions (ACP2, NR1H3, MADD, MYBPC3, and SPI1) were jointly tested for association with FG or BMI-adjusted ln(FI) using the sequence kernel association test (SKAT). 36 FHS used an SKAT that accounted for family structure. 37 SKATs were conducted within each of 3 cohorts and meta-analyzed using a weighted sum of squares of z-statistics from single-variant score tests. These variant scores were squared, weighted by a function of MAF, and summed to create a Q statistic. The significance of the Q statistics was determined using an asymptotic distribution, as described in Wu et al. 36 The Q statistic, calculated by taking the weighted squared z score for each variant and dividing by the total Q statistic, can be used to identify variants contributing most to the signal.
Primary rare variant analyses included all rare variants in each gene region. Secondary analyses included only variants that were considered likely to be functional based on annotation predictions (specifically, variants with RegulomeDB prediction scores 1-3, see Table II in the Data Supplement) in both noncoding and coding regions. To control type 1 error, a P value <0.05/20=0.0025 (corrected for 20 tests: 2 traits×5 gene regions×2 analyses) was used to define statistical significance for rare variant tests, where significance indicates that in aggregate the tested rare variants at the locus are associated with variation in FG and FI levels to a greater degree than expected by chance.
Common Variant Analyses
We tested common variants identified by deep sequencing for association with FG or BMI-adjusted ln(FI) using standard additive genetic linear regression models within each cohort. Mixed effects models were used in FHS to account for familial correlation. We meta-analyzed summary statistics from each cohort using standard fixed-effect inverse-variance weighted meta-analysis. 38 P values were obtained from unweighted regression models. Analyses weighted by the inverse of the sampling probability were used to obtain unbiased estimates of effect size. 4 To control type 1 error, the significance threshold for common variant analyses was set at P<2.16×10 −4 (0.05 corrected for 232 tests: 2 traits×116 variants).
Conditional Analyses
The MADD locus harbors 2 common variants (r 2 =0.07 in HapMap 2 CEU) associated with diabetes mellitus-related quantitative traits, rs794584 (associated with FG; Dupuis et al 2 ), and rs10838687 (fasting proinsulin levels; Strawbridge et al 3 ) . A second reported signal at MADD, rs10501320, was in high linkage disequilibrium with rs794584 (r 2 =0.924 in HapMap 2 CEU) and thus was not included in conditional rare variant analyses. The conditional analysis tested the hypothesis that these 2 known common variants explain (at least in part) the observed rare variant association at any of the 5 genes at 11p11.2. The conditional analysis was conducted by including the 2 common variants along with the rare variants at each of 5 gene regions in SKAT. In CHS and FHS, we used rs794584 and rs10838687, and in ARIC study, rs4752979 was used as a proxy for rs10838987 (r 2 =1.00 in HapMap CEU). Conditioned SKATs were conducted within each of the 3 cohorts and then meta-analyzed, with results compared with the unconditioned meta-analyzed SKAT P values. If unconditioned and conditioned P values are similar, this suggests that known common and novel and rare variation represent different signals at the locus.
All sequence variant-trait association analyses were conducted using custom scripts implemented in R 2.9.2. Adjustment for familial correlation (FHS) was done using the R kinship package. Functional assays were conducted using 8 replicates, and differences between groups in reporter assay results were tested using 2-sample t tests.
Results

Participant Characteristics
About half of the 3566 study participants without diabetes mellitus were women, the mean age ranged from 52 to 72 years, the mean BMI was in the overweight range, and mean FG was in the high-normal range ( Table 1) . FI values varied widely across studies, as have been observed previously. 2
Variants Identified by Targeted Deep Sequencing
Counts and characteristics of the rare and common variants identified by deep sequencing at 5 genes at the chromosome 11p11.2 locus are shown in Table 2 and Tables I and II in the Data Supplement. Deep (mean coverage, 38×) sequencing across 16.1 kb produced 653 variants, 79.9% (n=522) of which were rare and novel and 116 were common. Annotation information for coding and noncoding variation was available for 485 (74.3%) of the variants. These included 61 rare variants with RegulomeDB Prediction scores 1 to 3, suggesting potential effects on gene or chromatin regulation (Table II in the Data Supplement).
Rare Variant Associations With FI and FG
Meta-analyzed SKAT results (Table 3 and Figure 1 ) showed that 53 rare variants at the NR1H3 (nuclear receptor subfamily 1 group H member 3) locus were significantly associated with FI (P meta =2.73×10 −3 ). A subset of variants with RegulomeDB prediction scores 1 to 3 (n=7) was also significantly associated (P meta =1.28×10 −3 ) with FI. Four rare NR1H3 variants accounted for 74.6% of the overall SKAT Q statistic ( Figure 1B and Table III in the Data Supplement). One of these variants, chr11:47227430 (MAF=0.00068; 6 individuals in the source cohorts with the risk allele), accounted for 20.54% of the overall SKAT Q statistic. Chr11:47227430 was located in intron 2 of the longer isoform of NR1H3 in a predicted binding site for the FOXA1 transcription factor, with the A to G substitution altering the fifth position of the FOXA1 consensus motif ( Figure 1B inset) . FOXA1 is a key transcriptional regulator of hepatic and pancreatic development as well as insulin, glucagon, glucose, and adipocyte metabolism. 39, 40 Three individuals without diabetes mellitus carrying the A allele for this variant (n=1, n=1, n=1 in each of ARIC study, CHS, and FHS) had increased FI levels (ARIC study: 172.2 pmol/L; CHS: 194.5 pmol/L; FHS: 68 pmol/L) compared with their corresponding population mean (Table 1) , but in FHS, 7 individuals with the AG genotype (all were nondiabetic and no one had a AA genotype) had a similar FI level (72.0 pmol/L) compared with 2458 with the GG genotype (84.9 pmol/L; P=0.045). No additional rare variant associations were observed for FG or FI.
Common Variant Association Tests
None of the 116 common variants were significantly associated with FG or FI (see Figure I 
Conditional Analyses of Known Common Variants on Rare Variants Tests
SKAT of all 53 rare variants at NR1H3 conditioned on rs7944584 and rs10838687 eliminated the significance of their association with FI (P conditioned =0.08), but conditioned SKAT of the 7 highly functional variants remained significantly associated with FI (P conditioned =1.71×10 −3 ; Table 3 ).
Functional Characterization of the FI-Associated Variant at chr11:47227430
To assess the effects of the chr11:47227430 variant on FOXA1-mediated transactivation, we first used electrophoretic mobility shift assays to examine allele-specific disruption of FOXA1-DNA complexes using a well-characterized FB site located in the albumin gene enhancer (FB). 34 We found that the reference G allele at chr11:47227430 specifically and nearly completely displaced FB at its FB site at 10-fold excess, whereas a nonspecific competitor oligonucleotide did not displace FB at 100-fold excess (Figure 2A ). In addition, the reference G allele displaces binding of the FB oligonucleotide at much lower concentrations than the FI-associated A allele, suggesting that the G allele bound with greater stability. We confirmed these findings by showing that the reference G allele was bound directly by FOXA1 and that the FI-associated allele could not completely displace the reference G allele even at 100× molar excess, highlighting the higher affinity of the reference G allele toward FOXA1 ( Figure 2B ). The functional consequences of these differences in FB were assessed in transient transfection assays. We showed that the 280-bp region surrounding chr11:47227430 exhibited enhancer activity in HepG2 cells ( Figure 2C) , which was significantly elevated after overexpression of FOXA1 (Figure 2D) , supporting a role of FOXA1 in regulation of gene expression by binding to chr11:47227430. Most interestingly, the FI-associated A allele showed significantly reduced FOXA1-dependent transactivation ( Figure 2D and 2E ), suggesting that this variant reduces enhancer activity by attenuating FB.
Discussion
We performed deep resequencing at the multigene locus chromosome 11p11.2 in 3566 individuals of European ancestry from 3 cohort studies to identify rare, potentially functional variants associated with FG and FI, 2 key quantitative traits associated with type 2 diabetes mellitus physiology and risk. In the NR1H3 region, 7 rare variants predicted to be especially functional were significantly (after multiple-testing correction) associated with levels of FI, even after conditioning on 2 known glycemia-associated variants in MADD, suggesting that there are >2 independent signals at 11p11.2 and that the signal at NH1R3 is new. One of these 7 variants, chr11:47227430, seemed to account for a substantial portion of the gene-based signal. Chr11:47227430 lies in a binding motif for FOXA1, Table 1 a transcription factor implicated in glucose metabolism and insulin secretion. 39, 40 We showed in functional studies that the rare A allele of chr11:47227430 has a lower affinity to bind to FOXA1 compared with the reference G allele and disrupts FOXA1-mediated luciferase assay activity at the locus. Thus, we show that targeted deep resequencing in regulatory regions can identify new rare variants with previously unidentified regulatory activity. In the 3 subjects from the sequenced sample, carriers of the A allele seemed to have higher FI levels than their reference populations, but additional genotyping of the variant in FHS did not confirm that A allele carriers have a discernable phenotype. The chr11:47227430 variant is rare; additional genotyping in large numbers of additional samples is required to definitively determine whether variation at this base pair is associated with a discernable glucoregulatory phenotype. Finally, we found that no rare variants around any of the 5 genes were associated with FG and that no common variants at 11p11.2 were associated with FG or FI. Our results suggest that there is additional allelic heterogeneity associated with glucose and insulin regulation at the 11p11.2-MADD locus. Common polymorphisms have been identified through several GWASs at MADD, and here, we identify at the locus new rare variants with predicted regulatory function that seem to be independent of known common variation. Our findings complement the recent exome array analysis by Huyghe et al, 41 drawn from a Finnish cohort of 8229 men without diabetes mellitus. They found a mutation, rs35233100, encoding a stop codon Arg766 in MADD and associated with lower proinsulin levels. In this sample, rs35233100 was in modest linkage disquilibrium with rs7944584 and independent of rs1051006, pointing to MADD as a causal gene accounting for prior GWAS signals at the locus. However, proinsulin associations in their analysis were not completely eliminated by conditional analysis suggesting that additional variant(s) associated with insulin regulation at 11p11.2 remained to be identified. Our results from analysis of large numbers of deep sequences targeted at noncoding as well as coding variation suggest that rare regulatory variation at NH1R3 contributes to genetic glucose and insulin regulation and metabolism pathways encoded on chromosome 11p11.2. Notably, the 11p11.2 locus does not seem to be associated with risk of type 2 diabetes mellitus (T2D) in individuals of European ancestry, although may perhaps be weakly associated with T2D risk in Han Chinese. 42, 43 The locus seems to belong to the class of loci in which variants with relatively large effect sizes for glycemic traits (including FI and FG) show little risk for T2D (and vice versa). 42 Thus, our findings seem to bear more on physiological homeostatic regulation of glucose and insulin than on physiological pathways involved in the development of T2D.
. Characteristics of 3566 Participants Without Diabetes Mellitus in 3 Cohorts of European Ancestry in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Targeted Sequencing Study
The functional variant we detected lies in intron 2 of the longer of 2 isoforms of NR1H3, a plausible biological candidate gene. NR1H3, a nuclear hormone receptor, belongs to a family of ligand-activated transcription factors activated by cholesterol-derived compounds. NH1H3, also known as liver X receptor, plays a role in β-cell proliferation and mass. Liver X receptor mRNA levels are elevated in the pancreatic islets of animal models of type 2 diabetes mellitus, and in humans, liver X receptor elevation is associated with pancreatic β-cell dysfunction in T2D. 44, 45 The variant chr11:47227430 is predicted in RegulomeDB to alter a binding motif for FOXA1. We showed that the rare allele at chr11:47227430 had sequence-specific lower binding affinity for FOXA1, resulting in reduced FOXA1-mediated transactivation activity. FOXA1 (also known as hepatic nuclear factor 3α) belongs to the family of FOXA transcription factor genes critical for diverse biological processes relevant to glucose and insulin metabolism. Studies in mice lacking 1 or both FOXA1 alleles show impaired insulin secretion and P values from meta-analysis of multivariate SKAT analyses for fasting insulin and fasting glucose from 3 cohort samples. Included are results from all rare variants and the subset of variants with prediction scores between 1 and 3 obtained from RegulomeDB. 12 Variants with these prediction scores were predicted to be any (or a combination) of the following: transcription factor binding site, transcription factor motif, DNase Footprint, or DNase peak. Significance level: α<0.05/20=0.0025 (2.5×10 −3 ). GWAS indicates genomewide association study; and SKAT, sequence kernel association test.
*NR1H3 fasting insulin analyses were conditioning on GWAS variants rs7944584 and rs10838687 to access if known common variants explain (at least in part) the observed rare variant association.
glucose intolerance, and mice lacking FOXA1 expression develop a complex metabolic syndrome characterized by neonatal persistent hypoglycemia, pancreatic αand β-cell dysfunction, and increased expression of FOXA1 target genes. 46 Despite this supporting evidence, our data do not indicate that it is NH1R3, or in fact which gene at all, is the target influenced by variation at this transcript-specific intronic transcription factor binding site. Further functional work and correlation analyses using eQTL data in large cohorts in which the rare variant might be represented are needed to elucidate how and which target genes are influenced by the chr11:47227430 variant.
The CHARGE Targeted Sequencing Study represents a new generation of high-throughput deep sequencing studies focused on coding and noncoding variation underlying common cardiovascular disease and metabolic risk factors and diseases. Strengths of the study include a creative case-cohort design to assemble well-characterized cohorts of European descent. To analyze these data, a variety of new statistical methods and bioinformatics resources were developed, combined, and applied in a rigorous framework intended to limit type 1 error in the setting in which no similar data exist for replication. For instance, the high average sequence depth combined with rigorous quality control applied uniformly across 3 cohorts increased confidence that even the rarest observed variation is likely to be true variation and not technical artifact. Furthermore, we repeat-genotyped the 1 variant of interest identified by the sequencing approach. Type 2 error remains a limitation of the analysis; however, where a sample of 3566 individuals has limited power to detect common variant associations. For rare variants, the sample size gave just 3 individuals with the interesting, potentially functional mutation at chr11:47227430. Although high sequence depth is a strength, somewhat limited coverage breadth is a limitation.
The genomic segments selected for sequencing favored exons, but did include generous intronic flanking regions around exons and within and beyond regulatory regions flanking genes, thereby including far more noncoding variation than with strictly exome-based sequencing approaches. Unbiased whole-genome sequence in large numbers will be needed to define the true allelic spectrum of functional variation at 11p11.2. Of note is that mean BMI was in the overweight range in all 3 populations. However, effect sizes in known variants associated with glycemic traits do not differ between BMI strata. 35 In addition, notable heterogeneity was seen in FI levels across the 3 study populations, which might likely be a reflection of limited standardization of insulin assays. We have addressed these issues by adjusting for BMI, which improves ability to detect insulin resistance signals, 35 and furthermore, assay heterogeneity has not precluded the ability to detect novel variants in prior FI GWAS. 2, 35 Finally, our results include only people of European ancestry, so our analysis was further constrained by limited ancestral spectrum of human allelic variation at the 11p11.2-MADD locus.
In conclusion, deep sequencing at 11p11.2 in 3566 individuals from 3 European cohorts identified rare functional variation in an intron NR1H3 associated with FI. Conditional analysis suggests that known common variants near MADD and rare functional variants at NR1H3 seem to represent independent signals. Functional analysis showed the rare A allele at the chr11:47227430 reduced FB in vitro, resulting in reduced Figure 1. Regional plots for association of fasting insulin with common and rare variants at the chromosome 11p11.2 locus. A, Regional association at chromosome 11p11.2. The −log 10 P value of variant associations with fasting insulin is plotted on the left y axis vs chromosomal location on the x axis (NCBI Genome Build 36). Regions targeted for sequencing are marked with black boxes along the x axis. Common variant associations are shown as gray circles and rare variant associations as green arrows that mark the −log 10 P from meta-analysis of sequence kernel association test (SKAT) and the genomic position of the gene region containing the aggregate rare variants tested. DNase I hypersensitivity sites in pancreatic (blue dots) and hepatic cells (teal dots) are marked by their chromosomal position along the x axis. The regional recombination rate is plotted in light blue with values on the right y axis. The gray box indicates the NR1H3 region (meta-analysis P value=2.73×10 −3 ) that is expanded and shown in B. B, Regional plot of 53 rare variants at NR1H3 and their individual percent contribution to the overall regional metaanalytic SKAT Q test statistic. Variants with functional prediction 1 to 3 are shown as purple circles and variants with other functional prediction or without annotation by gray circles. The x axis shows the chromosomal position of the variants with the regions sequenced in black boxes. Additionally, DNase I hypersensitivity sites in pancreatic (blue dots) and hepatic cells (teal dots) and an ideogram for the NR1H3 gene body (green line) are marked. The left y axis shows the percent contribution of each variant to the overall meta-analysis SKAT Q statistic for the multivariant test at NR1H3. The marked variant chr11:47227430 is predicted to be functional and has a large contribution to the SKAT Q statistic. The regional recombination rate is plotted in light blue with values on the right y axis. The inset shows the consensus logo for the forkhead box A1 (FOXA1)-binding motif where the chr11:47227430 A to G substitution produces an adenine instead of a guanine in the fifth position, marked in the red box. The relative conservation of each nucleotide in the motif is displayed by its height. 12 FOXA1-mediated transcriptional activity in luciferase assays. Other genes localized to the MADD region-ACP2, MYBPC3, MADD, SPI1-showed no significant association of rare variants with either FI or FG levels. Our results suggest that in addition to previously demonstrated associations with common variation in MADD, rare variation at NH1R3 contributes to genetic glucose and insulin regulation and metabolism pathways encoded on chromosome 11p11.2. 
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